Genovis launches GingisREX™ and expands product portfolio

Genovis is launching GingisREX, a new enzyme aimed at customers throughout the
proteomics market. The products that Genovis has launched to date have been used
solely for modification of antibodies, while GingisREX can be used for proteins
in general.
Genovis’ products are marketed under the name SmartEnzymes™ and are used in the
biotech and pharmaceutical industries for characterization of biologics. What
sets GingisREX apart from the other enzymes in the product portfolio is that the
enzyme not only cleaves antibodies, it also cleaves other proteins specifically
after the amino acid arginine. GingisREX is extremely reliable and more precise
than similar enzymes on the market. It can be used alone or in combination with
Genovis’ other enzymes to improve analysis results.

“With the launch of GingisREX we are now focusing on the entire proteomics
market. Our customers currently use our enzymes for mass spec analysis and with
GingisREX we have now expanded the range for this customer group, at the same
time that we open up the available market. The product portfolio to date has
only included enzymes for analysis of antibodies, but it is now expanding to
include other proteins, and moving forward we intend to deliver several new
enzymes for the entire proteomics market. This is both challenging and
exciting,” says Fredrik Olsson, CEO of Genovis

For more information about GingisREX
www.genovis.com/gingisrex (http://www.genovis.com/gingisrex)
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and
medical device industries tools that facilitate and save time in the development
of new treatment methods and diagnostics. Today Genovis sells several enzyme
products known as SmartEnzymes all over the world in innovative product formats
that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc.
(USA).

Genovis shares are listed on Nasdaq First North Stockholm, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.